Previous studies have reported that CD151 activate PI3K/AKT signaling pathway to promote epithelial-mesenchymal transition (EMT) and SOR resistance 150, so SNHG3/miR-128/CD151 signaling can be used as a therapeutic target for HCC patients with SOR resistance. Here, AKT1 is linked to hepatocellular carcinoma.